About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT01152437

A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer

This Phase II study is open to patients with metastatic colorectal cancer who have tried but failed chemotherapy regimens containing oxaliplatin and irinotecan. Patients must not have received anti-EG...

Lead sponsor: Boehringer Ingelheim•13 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Boehringer Ingelheim

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patients with metastatic colorectal cancer who have failed both oxaliplatin- and irinotecan-based regimens
•2. Tumour sample available for KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation testing and other biomarker analyses.

Exclusion Criteria

•1. Prior treatment with Epidermal Growth Factor Receptor (EGFR) targeting small molecules or antibodies.
•2. Biological treatment (including Bevacizumab or any other antiangiogenic agents) during the trial is not allowed.
•3. Known pre-existing interstitial lung disease.
•4. Planned major surgical procedures during the trial period.

Related studies

RECRUITINGPhase 1

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319 · Colorectal Neoplasms, Gastrointestinal Neoplasms

Impact of SMS Messaging on Participation in Colorectal Cancer Screening

NCT07628998 · Colorectal Neoplasms, Early Detection of Cancer

Early Detection of Advanced Adenomas and Colorectal Cancer

NCT06342440 · Colorectal Cancer, Colorectal Neoplasms, and more

RECRUITINGPhase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786 · Colorectal Neoplasms

RECRUITINGPhase 1/2

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 26, 2014Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment94

Start dateJun 2010

Last updatedJun 26, 2014

Condition

Colorectal Neoplasms

Locations shown

1200.74.44001 Boehringer Ingelheim Investigational Site

Bournemouth

1200.74.44005 Boehringer Ingelheim Investigational Site

Bristol

1200.74.44006 Boehringer Ingelheim Investigational Site

Cambridge

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 26, 2014Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions